The pairing of Merck’s blockbuster immunotherapy Keytruda and Eisai’s Lenvima has previously failed in studies evaluating it in patients with types of head-and-neck cancer, skin cancer and colon cancer as well.

J&J’s therapy was tested in patients in whom the disease progressed even after they were treated with AstraZeneca’s Tagrisso.

The company said it will continue with its plan to file data from the trial with the FDA, soothing some investor concerns.

Four world-renowned oncologists selected 20 key, non-small cell lung cancer (NSCLC) abstracts presented at the American Society of Clinical Oncology (ASCO) annual conference. Their goal is to use their platform as educators to share unbiased perspectives on the studies’ clinical data, the methodologies, and its potential for improving patient outcomes in lung cancer.

Although an experimental precision drug slowed progression of lung cancer in a late-stage trial, the company’s shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped.

The Phase III trial, which can potentially lead to a regulatory filing, will enroll about 600 patients, the companies said in a statement on Thursday.

The therapy is the first in more than seven years to show a significant extension in overall survival in metastatic non-small cell lung cancer (NSCLC) in late-stage study.

The latest data, presented at the American Society of Clinical Oncology (ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer.

The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.

G1 Therapeutics Inc. said on Monday it would terminate a late-stage study of its lead drug as it was unlikely to be effective in extending survival in patients with a type of colorectal cancer, sending its shares plunging more than 50%.